# A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

> **NCT03104413** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 618 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** placebo for risankizumab IV
- **DRUG:** risankizumab SC
- **DRUG:** risankizumab IV

## Key facts

- **NCT ID:** NCT03104413
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-18
- **Primary completion:** 2020-11-30
- **Final completion:** 2021-05-19
- **Target enrollment:** 618 (ACTUAL)
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03104413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03104413, "A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03104413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*